The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Etoposide in Treating Young Patients With Relapsed Ependymoma
Official Title: Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma
Study ID: NCT00278252
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well etoposide works in treating young patients with ependymoma.
Detailed Description: OBJECTIVES: Primary * Determine the response rate in young patients with relapsing and/or refractory ependymoma treated with a rapid schedule of intravenous etoposide. Secondary * Determine the possibility of second surgery or additional radiotherapy in these patients. OUTLINE: This is a multicenter study. Patients receive etoposide IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients whose tumor becomes resectable after courses 3 or 6 undergo surgical resection. After completion of study treatment, patients are followed periodically for approximately 5 years. PROJECTED ACCRUAL: At least 14 patients will be accrued for this study.
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Name: Linda S. Lashford
Affiliation: The Christie NHS Foundation Trust
Role:
Name: Susan V. Picton, MD
Affiliation: Leeds Cancer Centre at St. James's University Hospital
Role: STUDY_CHAIR